#cdsco
Wockhardt shares jump 8%, extend rally after CDSCO nod for Zaynich antibiotic
Wockhardt shares surged after the company received CDSCO approval for its breakthrough antibiotic Zaynich in India. Strong Phase 3 trial results and the drug’s potential to treat severe drug-resistant infections boosted investor sentiment, helping the stock e…
Wockhardt stock rallies post - CDSCO nod for novel antibiotic
Wockhardt gets CDSCO nod for Zaynich antibiotic
Wockhardt Ltd has secured approval from the CDSCO for its new antibiotic, Zaynich. This drug is developed in India and will be used to treat complicated urinary tract infections in adults. The approval follows successful clinical trials. Zaynich shows potenti…
india-rx-mcp 0.1.1
MCP server for Indian pharma regulatory data (CDSCO approvals + NPPA pricing)
india-rx-mcp added to PyPI
MCP server for Indian pharma regulatory data (CDSCO approvals + NPPA pricing)
india-rx-mcp 0.1.0
MCP server for Indian pharma regulatory data (CDSCO approvals + NPPA pricing)
Drugmakers must report safety data from launch date, not approval date: CDSCO
India's drug regulator has issued a new directive for pharmaceutical companies. Periodic Safety Update Reports for new drugs must now be submitted from the actual market launch date. This change aims to strengthen patient safety monitoring. Previously, report…